[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-334346-105":59,"doc-detail-334346-en":134},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":127,"head_meta":129,"extra_data":131,"updated_unix":133},105,"en","correlation-of-pd-l1-expression-with-different-clinico-pathological-and-immunohistochemical-features-of-ovarian-surface-epithelial-tumors","Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors","","Ovarian primary carcinoma accounts for substantial cancer mortality, and PD-1 signaling is a key immune checkpoint that suppresses T-cell activation and promotes immune tolerance. This study assessed immunohistochemical PD-L1 expression in 102 primary ovarian surface epithelial tumor cases (benign, borderline, malignant) using tissue microarrays and examined associations with clinicopathological parameters and a marker panel including P53, ER, and PR. Malignant tumors showed higher PD-L1 positivity and combined PD-L1 with PR or ER positivity; no significant correlations were observed with individual parameters. PD-L1 marker panels may help identify patients who could benefit from immunotherapy.",{"@graph":69,"@context":126},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/correlation-of-pd-l1-expression-with-different-clinico-pathological-and-immunohistochemical-features-of-ovarian-surface-epithelial-tumors/334346/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/correlation-of-pd-l1-expression-with-different-clinico-pathological-and-immunohistochemical-features-of-ovarian-surface-epithelial-tumors/334346.png","ImageObject",300,407,{"name":92,"@type":93},"Aurelia","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-12","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":34},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118,122],{"name":109,"@type":110,"acceptedAnswer":111},"What was the main purpose of this study?","Question",{"text":112,"@type":113},"To evaluate immunohistochemical PD-L1 expression in primary ovarian surface epithelial tumors and test its correlation with clinicopathological parameters and marker panel expression (P53, ER, PR).","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"How were the tumor samples and immunohistochemistry performed?",{"text":117,"@type":113},"A set of 102 cases was assembled into a tissue microarray using three tissue cores per case, followed by immunohistochemical staining for PD-L1, p53, PR, and ER.",{"name":119,"@type":110,"acceptedAnswer":120},"What were the key findings regarding PD-L1 in malignant versus borderline/benign tumors?",{"text":121,"@type":113},"PD-L1 expression was detected in about 51% of malignant tumors, and malignant tumors showed significantly higher PD-L1 positivity than borderline and benign groups. Combined PD-L1 positivity with PR or ER was also higher in malignant tumors.",{"name":123,"@type":110,"acceptedAnswer":124},"Did PD-L1 expression correlate with the studied clinicopathological parameters?",{"text":125,"@type":113},"No significant correlation was appreciated between PD-L1 expression and any of the studied clinicopathological parameters.","https://schema.org",{"og:url":83,"og:type":128,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":130,"canonical":83},"index,follow",{"doc_id":132,"site_id":62},334346,1790012961,{"code":4,"msg":5,"data":135},{"doc_id":132,"user_id":136,"nickname":92,"user_avatar":137,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":34,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":34,"language":143,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":67,"update_tm":147,"read_time":148,"preview_page_count":4},1099514068365,"https://ap-avatar.wpscdn.com/avatar/10000253d8d9f28188e?x-image-process=image/resize,m_fixed,w_180,h_180&k=1794309523707217728","Clinical and Translational Oncology (2025) 27:699–705  \n[https://doi.org/10.1007/s12094-024-03613-2](https://doi.org/10.1007/s12094-024-03613-2)  \nCorrelation of PD‑L1 expression with different clinico‑pathological and immunohistochemical features of ovarian surface epithelial tumors  \nAsem Shalaby1,2 · Ola Shalaby1 · Hazem Abdullah3 · Mohamed Rachid Boulassel4,5 · Mohammad Arafa1,2  \nReceived: 18 May 2024 / Accepted: 9 July 2024 / Published online: 1 August 2024 © The Author(s) 2024  \nAbstract  \nBackground Primary carcinoma of the ovary (OCs) are responsible for a significant number of deaths related to cancer, and have the highest rate of death related to cancers of the female reproductive organs. Programmed cell death 1 (PD1) protein, acts as an immune checkpoint, and has an important role in the down-regulation of the immune system by preventing the activation of T-cells, which will weaken the autoimmunity and increases self-tolerance. This study aimed at the evaluation of the immunohistochemical (IHC) expression of PD-L1 in various primary surface ovarian epithelial tumours and to test its correlation with different clinicopathological parameters together with the expression of a panel of P53, ER and PR. Methods A set of 102 cases of primary ovarian surface epithelial neoplasms (benign, borderline and malignant) were collected to construct Tissue Microarray (TMA) using 3 tissue cores from each case. IHC for PD-L1, p53, PR and ER was performed. The expression of PD-L1 was evaluated in relation to some clinicopathological parameters and to the expression patterns of other markers.  \nResults Expression of PD-L1 was detected in about 51%(n = 36) of malignant tumours. The malignant group significantly showed PD-L1 positivity compared to borderline and benign groups. The malignant tumours significantly showed PD-L1 and total p53 positivity in comparison to borderline group. Also, malignant tumours significantly showed higher combined positivity of PD-L1 and either PR or ER compared to borderline and benign lesions. No significant correlation was appreciated between PD-L1 expression and with any of the studied clinicopathological parameters.  \nConclusions This study showed a significant PD-L1 expression in malignant primary surface epithelial tumours. Construction of a panel of IHC markers, including PD-L1, could have a potential value to define patients those would benefit from the addition of immunotherapy to the treatment plan.  \nKeywords PD-L1 · Carcinoma · ER · PR · P53  \n* Asem Shalaby  \n[asemali444@yahoo.com](asemali444@yahoo.com); [a.shalaby@squ.edu.om](a.shalaby@squ.edu.om);  \n[asemali@mans.edu.eg](asemali@mans.edu.eg)  \n1 Pathology Department, Faculty of Medicine,, Mansoura University, Mansoura, Egypt  \n2 Pathology Department, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman  \n3 Pathology Department, Faculty of Medicine, Damietta University, Damietta, Egypt  \n4 Department of Hematology, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman  \n5 Department of Biomedical Science, College of Medicine and Health Sciences, Sultan Qaboos University, Muscat, Oman  \nAbbreviations  \nPD-L1 Programmed cell death ligand 1  \nOCs Ovarian carcinomas ER Estrogen receptors PR Progesterone receptors PD 1 Programmed cell death  \nIHC Immunohistochemical  \nBackground  \nOvarian primary malignant epithelial neoplasms, known as ovarian carcinomas (OCs), constitute a significant fraction of deaths related to cancer in women and has the highest cancer related death rate amongst cancers of the female reproductive organs. The disease is lethal particularly due  \nto late initial presentation and the lack of early diagnosis due to its vague symptoms [1, 2]. Traditionally, ovarian tumours can be grouped into two distinct types [2, 3] . Type I represents about 30% of ovarian cancers. It is genetically stable, slowly growing, and comprises low-grade serous, endometrioid, clear-cell, and mucinous ","cbCaikfTss7HGtZ4","https://ap.wps.com/l/cbCaikfTss7HGtZ4","pdf",769579,"English","# Abstract\n## Background\n## Methods\n## Results\n## Conclusions\n# Background\n## Ovarian carcinoma types and prognosis\n## Need for improved therapeutic strategies\n## PD-1/PD-L1 pathway and rationale","[{\"question\":\"What was the main purpose of this study?\",\"answer\":\"To evaluate immunohistochemical PD-L1 expression in primary ovarian surface epithelial tumors and test its correlation with clinicopathological parameters and marker panel expression (P53, ER, PR).\"},{\"question\":\"How were the tumor samples and immunohistochemistry performed?\",\"answer\":\"A set of 102 cases was assembled into a tissue microarray using three tissue cores per case, followed by immunohistochemical staining for PD-L1, p53, PR, and ER.\"},{\"question\":\"What were the key findings regarding PD-L1 in malignant versus borderline/benign tumors?\",\"answer\":\"PD-L1 expression was detected in about 51% of malignant tumors, and malignant tumors showed significantly higher PD-L1 positivity than borderline and benign groups. Combined PD-L1 positivity with PR or ER was also higher in malignant tumors.\"},{\"question\":\"Did PD-L1 expression correlate with the studied clinicopathological parameters?\",\"answer\":\"No significant correlation was appreciated between PD-L1 expression and any of the studied clinicopathological parameters.\"}]","Correlation of PD-L1 expression with different clinico-pathological and immunohistochemical features of ovarian surface epithelial tumors | PDF",1790006330,18]